Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C61H63N9O17S4.4Na |
Molecular Weight | 1414.422 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].[Na+].CC1(C)\C(=C/C=C2\CCCC(\C=C\C3=[N+](CCCCS([O-])(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C([O-])=O)C=C5)N(CCCCS([O-])(=O)=O)C9=C1C=C(C=C9)S([O-])(=O)=O
InChI
InChIKey=LRVBSDMJFVZFHH-NFVAJSDSSA-J
InChI=1S/C61H67N9O17S4.4Na/c1-60(2)46-33-44(90(81,82)83)22-24-49(46)69(28-5-7-30-88(75,76)77)51(60)26-16-38-10-9-11-39(17-27-52-61(3,4)47-34-45(91(84,85)86)23-25-50(47)70(52)29-6-8-31-89(78,79)80)54(38)87-43-20-12-37(13-21-43)32-48(58(73)74)66-56(71)40-14-18-41(19-15-40)63-35-42-36-64-55-53(65-42)57(72)68-59(62)67-55;;;;/h12-27,33-34,36,48H,5-11,28-32,35H2,1-4H3,(H9-,62,63,64,66,67,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86);;;;/q;4*+1/p-4/t48-;;;;/m0..../s1
Molecular Formula | C61H63N9O17S4 |
Molecular Weight | 1322.463 |
Charge | -4 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 3 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
OTL-0038 or OTL-38, a fluorescent-labelled folate receptor-α (FRα) targeted imaging agent that accumulates in vivo in tumor cells expressing FR. OTL38 is currently in ongoing Phase 3 clinical trial in ovarian cancer and successfully completed phase 2 clinical trial in lung cancer. OTL38 is being evaluated for its ability to help surgeons locate and remove hard-to-find cancerous lesions that are often widespread. In 2014, the OTL-38 molecule was granted orphan drug status which can be given to the maker of a drug that treats rare conditions or diseases and offers protection from competition for a period of time. In addition, OTL-38 was studied in phase II clinical trials in the Netherlands for the diagnosis of endometriosis.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors: a patent evaluation of US20160011199A1. | 2016 Nov |
|
Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. | 2018 Jan 2 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03180307
0.025 mg/kg of OTL38 (OTL-0038) in 250ml D5W infused intravenously over 60 minutes
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:30:40 GMT 2023
by
admin
on
Sat Dec 16 10:30:40 GMT 2023
|
Record UNII |
4HUF3V875C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1628858-03-6
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
HI-70
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
2586858
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
135564971
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
300000028916
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
4HUF3V875C
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
4HUF3V875C
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
C175835
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
PRIMARY | |||
|
1628423-78-8
Created by
admin on Sat Dec 16 10:30:41 GMT 2023 , Edited by admin on Sat Dec 16 10:30:41 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|